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cardiovascular surgeons. Dramatic advances in the techni-
cal expertise for performing thoracic aortic surgical repairs
and for determining the indications for appropriate candi-
dates have advanced over the last years.1-4 Despite the
clinical and procedural expertise that has developed, re-
pair of thoracic aneurysms remains with high morbidity
and mortality with interventions reserved for patients who
are at significant risk for complications related to the
aneurysm if untreated.
With the development of endovascular prostheses to
treat abdominal aortic aneurysms (AAAs), a concomitant
effort to adapt this technology to the treatment of
descending thoracic aneurysms has demonstrated promis-
ing preliminary results with a decrease in both major mor-
bidity and mortality being noted in many patients.
Although the experience is preliminary, the magnitude of
the surgical procedure and the decreased incidence of
morbidity and mortality with endovascular repairs support
further evaluation of this technology.5-10
Determining the indications for repair of thoracic aor-
tic aneurysms (TAAs) presents a challenging problem for
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Objective: The objective of this study was to analyze a single-center experience in which descending thoracic aortic
aneurysms (TAAs) were treated with a new self-expanding endovascular prosthesis (Medtronic AVE).
Methods: Twenty-six patients (13 men, 13 women) with American Society of Anesthesiology grades II to IV and ages rang-
ing from 53 to 92 years (average, 74 years) consented as part of a Phase I Food and Drug Administration–approved trial.
Treated lesions included TAAs that were 5 to 10 cm in diameter, 12 diffuse dilations or fusiform aneurysms, and four
saccular aneurysms. There were also nine chronic dissections (2 aneurysmal dilations and 7 symptomatic acute recurrent
dissections). Three patients (2 with diffuse/fusiform and 1 with dissection) presented with hemothorax, contrast extrava-
sation, or both.
Results: Twenty-five of the 26 patients who consented (96% technical success) were treated successfully with no surgical
conversions. Eighteen patients have been followed up from 1 to 22 months (average, 9 months). One patient is lost to
follow-up, and six patients have died (24%). One procedure-related death (4%) occurred within the 30-day postoperative
period and was caused by diffuse embolization. There were no device-related deaths. Five additional patients (20%) have
died during the study of comorbid conditions. Complications included one massive myocardial infarction 24 hours after
the procedure requiring balloon counterpulsation and long-term dialysis, one cardiac tamponade resulting from central
line placement before the procedure, one progression of aneurysm dilation proximal to the device at 1 year, and one bilat-
eral lower extremity paralysis occurring 12 hours after successful deployment. Seven patients (5 women) had femoral
artery reconstructions or iliac artery grafts to repair injuries during deployment catheter passage. Other significant param-
eters included average procedure time (2 hours 40 minutes; range, 1 hour 30 minutes to 5 hours 30 minutes), 450 cc
average blood loss (n = 25; 100-3000 cc) being replaced by means of autotransfusion with only two patients receiving
banked blood products, and an average 2 days to resumption of normal diet, 1 day in the intensive care unit, and 5 days’
hospitalization postprocedure in uncomplicated cases (n = 22). One patient had an endoleak immediately after the pro-
cedure that sealed without treatment. Follow-up of all patients ranging from 1 to 22 months (average, 9 months; n = 18)
demonstrates continued exclusion of the aneurysm with no endoleaks and either stable or decreasing aneurysm volume,
except in one patient with volume increase and no obvious etiology who continues to be investigated.
Conclusions: The study suggests that endovascular prosthesis exclusion of TAAs with an AneuRx self-expanding tubu-
lar device may be effective in many patients who are at significant risk for open surgical repair and substantiates fur-
ther clinical investigation to confirm these findings. (J Vasc Surg 2001;33:927-34.)
This report describes a one-center experience with the
treatment of descending TAAs and dissections with the
Medtronic AVE AneuRx thoracic endovascular prosthesis
(Santa Rosa, Calif) and offers a perspective on the future
utility of this new technology.
METHODS
The objective of the study was to analyze the single-
center experience during descending TAA repair with a
self-expanding nitinol stent and polyester fabric-lined
endovascular device (Medtronic AVE). All patients were
entered into a protocol approved by the Institutional
Review Board at our institution and signed consent forms
for the investigational devices and surveillance protocols
used to generate the data reported. The inclusion and
exclusion criteria for the study are detailed in Table I.
Patients who were treated who did not meet the entry cri-
teria for the study were designated as off protocol emer-
gency use.
Medtronic AneuRx device. The Medtronic AneuRx
thoracic device is made of identical materials and is
deployed by means of the same mechanisms as the
AneuRx bifurcated abdominal aortic device.11,12 The
polyethylene, fabric-covered, self-expanding nitinol stents
are deployed with a 23F delivery catheter. The thoracic
devices are supplied in 6- and 12-cm length modular com-
ponents with the outside diameter of the devices being 32,
36, and 40 mm. Complete overlap of at least 2 cm is rec-
ommended for modular components with more overlap
needed for severely angulated segments. A stent oversized
at 10% to 20% compared with the diameter of the fixation
sites is recommended.
Clinical data. Twenty-six patients (13 men, 13
women) with American Society of Anesthesiology grades
II to IV and ages ranging from 62 to 92 years (average, 74
years) consented as part of a Phase I Food and Drug
Administration trial. Twenty-one patients met the entry
criteria for the study, and five patients were treated as
emergency use. All procedures were performed in a spe-
cially designed endovascular surgical suite with most
patients receiving local anesthesia for the groin incisions
supplemented by hypnotic and systemic analgesics as
needed. Treated lesions included TAAs that were 5 to 10
cm in diameter (12 diffuse dilations or fusiform aneurysms
and 4 saccular aneurysms). In addition, nine chronic dis-
sections (2 aneurysmal dilations and 7 symptomatic recur-
rent dissections that failed medical management) were
treated. Three patients (2 diffuse/fusiform and 1 dissec-
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Table I. Entrance criteria
Inclusion criteria Exclusion criteria
Signed informed consent The stent graft would have to be positioned such that there would 
be no flow to an artery, major branch artery, or major branch 
arteries that supply the spinal cord
Patient is a candidate for repair of a descending The patient has congential abnormalities in which the placement of
thoracic aortic aneurysm the stent graft will cause occlusion of major arterial flow. 
Such abnormalities should be evaluated (eg, angiography or CT) 
before treatment
Patient has one or more of the following Pregnancy
Descending thoracic aneurysm, 5 cm in diameter or greater  Morbid obesity or other clinical conditions that severely inhibit 
with proximal and distal neck suitable for stent graft placement x-ray film visualization of the aorta
Aneurysm is 4-5 cm in diameter with an increase in Connective tissue diseases (eg, Marfan syndrome)
size by 0.5 cm in last 6 mo
Maximum diameter of aneurysm exceeds 11⁄2 times the Hypercoagulability disorder
transverse dimension of an adjacent normal aortic segment
Post-traumatic pseudoaneurysm Acute renal failure
Postsurgical pseudoaneurysm Systemic infection
Saccular aneurysm Younger than 18 y
Contained rupture Less than a 1-y expectancy
Penetrating ulcer Patient is participating in another research study involving an 
investigational agent for the treatment of descending TAAs
Patient’s vascular dimensions (eg, aortic diameters, length Other medical, social, or psychological issues that in the opinion of
from left subclavian to celiac artery) must be in the range the investigator preclude patients from receiving this treatment
then be safely treated with the stent graft and extensions and the procedures and evaluations before and after treatment
available to the physician at the time of the procedure
Patient has patent iliac or femoral arteries or acceptable Unwillingness or inability to return for or comply with follow-up
retroperitoneal access via the abdominal aorta that allows visit schedules
endovascular access to the aneurysmal site with a 23F 
delivery or delivered through 24F introducer sheath
Patient has a nonaneurysmal proximal and distal aortic neck 
diameter between 25 and 36 mm
Patient is American Society of Anesthesiology grade I through IV
Patient is able and willing to comply with 1-mo, 6-mo, and 
1-y follow-up and willing to comply with annual 
posttreatment follow-up requirements thereafter
tion) presented with hemothorax, contrast extravasation,
or both. Two patients had both TAAs and AAAs that were
treated simultaneously, and one patient with a thoracoab-
dominal dissection had staged repair of the thoracic entry
site and aneurysmal dilation and 1 month after this, had a
65-mm AAA excluded with a bifurcated AneuRx device.
Where possible, patients had computed tomography
(CT) images before the procedure and at 1 month, 6
months, and 1 year to assess the success of aneurysm
exclusion and to observe the morphologic characteristics
of the aneurysms. Desired CT parameters were for heli-
cal/spiral mode with slice reconstruction at 2 or 3 mm,
collimation 5, and pitch 1:1.5. The original data sets from
the spiral CT scans were used to determine the total vol-
ume, aortic aneurysm thrombus volume (TAA volume
minus the volume of the device and the luminal blood
flow). In patients with dissections, the data were used to
calculate the total TAA; lumen and thrombus volume, 
if an aneurysm was present; or the true and false luminal
volumes of the dissection at sequential periods after
deployment of the device. The CT angiograms were
reconstructed in an interactive environment (Medical
Media Systems [MMS], West Lebanon, NH). Diameters
and aortic segments were measured in a plane perpendic-
ular to the centerline of the aortic lumen rather than in
slices perpendicular to the body of the patient, as is done
when conventional CT images are used, to completely use
an interactive environment.
RESULTS
Twenty-five of 26 patients were successfully treated
(96% technical success) with no surgical conversions. The
one technical failure was in a patient who had inadequate
access to introduce the device through the femoral artery.
This patient is currently rescheduled for a second attempt
at deployment via a retroperitoneal approach. Eighteen
patients have been followed up from 1 to 22 months
(average, 9 months). One patient is lost to follow-up, and
six patients have died (24%) (Table II). One procedure-
related death (4%) occurred within the 30-day postopera-
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tive period and was caused by diffuse embolization to mul-
tiple organ systems including the brain, viscera, and
extremities and was most likely caused by guidewire injury
to the severely diseased ascending and transverse aorta
during the procedure. There were no device-related
deaths. Five additional patients (20%) have died during
the study of comorbid conditions.
Complications included one massive myocardial
infarction 24 hours after the procedure requiring balloon
counterpulsation and renal dialysis in a patient who had
both TAAs and AAAs treated simultaneously, one cardiac
tamponade resulting from central line placement, one pro-
gression of aneurysmal enlargement proximal to the
device at 1 year, and one bilateral lower extremity paraly-
sis/paresis occurring 12 hours after successful deploy-
ment. Seven patients (5 women) had femoral artery
reconstructions or iliac artery grafts to repair injuries dur-
ing deployment catheter passage or to provide adequate
access for the 24F deployment catheters. Other significant
procedural parameters included an average procedure time
of 2 hours 40 minutes (n = 25; range, 1 hour 30 minutes
to 5 hours 30 minutes), 450 cc average blood loss, (n =
25; 100-3000 cc), and an average of 2 days to resumption
of normal diet, 1 day in the intensive care unit, and 5 days’
hospitalization postprocedure in uncomplicated cases (n =
22). Blood replacement in all but two patients was accom-
plished by means of autotransfusion during the procedure.
One patient had an endoleak immediately after the proce-
dure that sealed without treatment.
Sequential images of all patients ranging from 1 to 22
months (average, 9 months; n = 18) demonstrated that
volumes of saccular aneurysms either remained stable or
decreased over the first 6 to 12 months postprocedure in
all but one patient who had an increase in aneurysm vol-
ume of 20% without evidence of an endoleak. The etiol-
ogy for the continued enlargement of the aneurysm in this
patient is being investigated (Figs 1 and 2).
Table III lists the patients with aortic dissections who
were treated and describes the indications for intervention
and outcomes. Serial images of patients with successful
Fig 1. Serial three-dimensional images of a 93-mm thoracic aneurysm with exclusion demonstrated on the 72-hour CT before discharge
and continued exclusion and regression of the aneurysm on the 14-month follow-up study. During this interval, the maximum diame-
ter of aneurysm decreased from 93 to 72 mm. Volume studies performed at same intervals demonstrate a decrease in total TAA volume
from 519 to 422 cc, with blood flow volume increasing from 141 to 176 cc. TAA thrombus volume also decreased from 353 to 218 cc
as aneurysm regressed.
exclusion of descending and abdominal aortic dissections
showed a decrease in the blood flow volume of the false
lumen, whereas the total volume of the true and false
lumen remained the same (Fig 3).
DISCUSSION
TAAs are frequently asymptomatic and are diagnosed
incidentally as part of other medical evaluations. They also
appear with acute chest pain related to extension of
chronic dissections or to perforation of the aortic wall.
Untreated patients with TAAs have been reported to have
high mortality both from unassociated causes and as a
result of aneurysm rupture.13,14 Survival has been
improved with operative intervention; however, TAA
repair continues to be associated with high morbidity and
mortality.1-4 A significant incidence of postoperative para-
plegia and other complications including renal failure and
long recovery periods related to comorbid medical condi-
tions (eg, coronary artery disease, pulmonary disease) is
frequently encountered.
The treatment of descending TAAs and dissections
with several prototype endovascular devices has been
promising. Investigators have reported success in the
treatment of patients with asymptomatic fusiform and sac-
cular thoracic aneurysms, chronic dissections, and pene-
trating ulcerated plaques.5-10 After successful initial use of
this technology with “homemade” devices, several manu-
facturers now are pursuing clinical devices with investiga-
tors evaluating the mid- and long-term utility of these
prostheses. Newer devices are being developed to treat
ascending and arch aneurysms with prostheses crossing
and maintaining patency of branches arteries or by devel-
oping ways to cannulate the side branches with specially
designed prostheses so that the eventual treatment of the
entire length of the thoracic aorta may be possible.15
In addition to the treatment of fusiform and saccular
thoracic aneurysms, endovascular prostheses have also
been used to treat acute extensions of chronic dissections
that appear with recurrent symptoms and severe pain and
do not respond to medical management.5-7 There are also
significant data regarding the endovascular treatment of
aneurysmal enlargement of the aorta following dissection.
A particularly promising area for future development is the
use of endovascular devices to treat acute aortic dissec-
tions. Preliminary data suggest that early intervention may
limit the extent of the dissection.
In this study we treated two patients with TAA and
AAA by simultaneously deploying endografts during the
same procedure. Although the deployment of the devices
was successfully accomplished in both cases, one patient
had a massive myocardial infarction 24 hours postproce-
dure, which significantly prolonged his hospitalization and
eventually contributed to his death of cardiac decompen-
sation. The second patient was a high-risk patient with car-
diomyopathy and an ejection fraction of 15% who was
successfully treated in less than 2 hours while receiving
only local anesthesia (Fig 4). He was fully active within 48
hours and has had an uneventful recovery. A third patient
with a thoracoabdominal dissection had staged repair of
the thoracic entry site and aneurysmal dilation; 1 month
later the patient had a 65-mm AAA excluded with a bifur-
cated endograft. One unresolved issue regarding the treat-
ment of TAA and AAA simultaneously is whether the
outcome is favorable compared with treatment of the
aneurysms at separate settings. Although there is concern
that there may be an increased risk of adverse events by
combining the procedures, such as paraplegia, we did not
encounter this in our limited experience.
Paralysis is one of the most feared complications after
repair of thoracic aneurysms. The one patient who had
paralysis postprocedure in this study had the onset 12
hours after deployment. We immediately began spinal
drainage with only limited improvement. The etiology of
paralysis in this patient is unknown because we did not
cover identifiable aortic branch vessels in the excluded seg-
ment. One possible cause is that we had one attempted
deployment of the endograft from one femoral artery, but
the attempt was unsuccessful because of inadequate access.
At a later date, the thoracic endograft was successfully
deployed from the opposite groin through a common iliac
artery conduit. One possible etiology for the paralysis is
compromise of the pelvic circulation by bilateral hypogas-
tric/pelvic circulation disturbances during access
attempts. It has now been approximately 8 weeks since the
procedure, and the patient has limited movement of both
legs and is being bladder and bowel trained. Others have
reported a similar delayed onset of paralysis with, in most
cases, the etiology being unknown.7,16
Significant advances have led to lower the incidence
of neurologic deficit during surgical repair of thoracoab-
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Fig 2. Sequential volume reconstructions of 10-cm saccular
aneurysm after exclusion. By 4 months postprocedure (March 23,
2000), total aneurysm volume decreased from 616 to 442 cc with
concomitant increase in blood flow lumen from 200 to 235 cc
and a decrease in thrombus volume from 361 to 160 cc.
dominal aneurysms from 30%-40% to 8%-10% with sev-
eral adjunctive techniques.1,2,17-19 These include left
atrial femoral bypass grafts, which enable increased spi-
ral cord perfusion during the procedure; hypothermia;
cerebrospinal fluid drainage; and systematic reimplanta-
tion of intercostal arteries. In our patients we did not
use any adjuncts to prevent neurologic complications
aside from careful manipulation of diseased vessels with
guidewires and delivery catheters and an attempt to pre-
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vent hypotension postprocedure that might precipitate
cord ischemic events.
As with many other types of endovascular prosthe-
ses, particularly those used to exclude AAAs, the mor-
bidity and mortality associated with the endovascular
repair of thoracic aneurysms appear to be significantly
less than conventional operative treatment. Not only is
there reduced mortality, but the associated morbidity,
such as paraplegia, renal failure, and pulmonary com-
Fig 3. Serial CT images of 67-year-old woman with severe pain from extension of thoracoabdominal dissection. Patient was treated with
thoracic endograft with entry site (arrow) in thoracic segment being covered by device. No distal reentry was performed because the
false lumen reentered in the left common iliac artery (double arrow) and partially perfused the left renal artery retrograde via the false
lumen in abdominal aortic dissection. Serial interactive images demonstrated that volumes of true and false lumens remained the same
in the chest and along thoracoabdominal dissection from top of the endograft through bifurcation of aorta. False lumen in the endo-
graft thrombosed while the volume of thrombus in dissection below the endograft increased from 103 to 164 cc while blood flow lumen
in the dissection decreased from 103 to 45 cc.
Table II. Mortality
Patient no. Presentation Clinical course Cause of death
1 Perforated, diffusely dilated thoracic aorta Hospitalized 17 d, complete Congestive heart failure 2 mo 
with hemothorax; renal and cardiac failure recovery by 30 d with CT scan postprocedure
demonstrating exclusion
2 70-mm TAAs, 50-mm AAAs Massive myocardial infarction Died 6 wk postprocedure of 
24 h postprocedure hospitalization irreversible cardiac debility
19 d with discharge to convalescent 
facility
3 75-mm saccular aneurysm Recovery uneventful for 1⁄2 h, then Microembolization with 
pulseless limb and reoperation. diffuse organ involvement 
Never woke after surgery and died including brain, viscera, and
at 1 wk of massive stroke and extremities
organ ischemia
4 Emergency use–thoracic dissection with Three-d hospitalization, complete Renal and pulmonary failure  
severe pain and contrast extravasation recovery of unknown etiology 3 mo 
postprocedure
5 A 92-year-old woman, 80-cm fusiform Procedure uneventful; cardiac Sepsis resulting from infected
aneurysm tamponade 12 h postprocedure chronic gastrostomy site for 
from central line with recovery by 7d longstanding ulcerative colitis
6 Emergency use–prior lower thoracic Uneventful recovery with discharge Liver failure suspected as a result
aneurysm resection, expanding upper 6 d postprocedure of hepatitis from transfusions 
thoracic segment to 70 mm with pain during prior hospital admissions
promise, is reduced because many patients can be
treated while receiving local anesthesia with shorter hos-
pital stays and quicker recovery. Obviously, the long-
term utility of this technology awaits further
investigation, although short- and intermediate-term
results are encouraging in these high-risk patients.
We acknowledge the contribution made by Peter
Robbie, Medical Media Systems, Inc, and Kelly Burke,
Research Assistant, who provided the Preview surgical
software analysis in this manuscript.
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Table III. Patients with aortic dissections
Follow-up Aneurysm diameter
Patient no. postprocedure (mo) Symptoms at intervention (mm) Outcome
1 22 Chronic dissection; aneurysm 57 Pain resolved and aneurysm size 
enlargement > 5 mm last 6 mo, stable; aneurysmal enlargement has 
recurrent chest and back pain continued in proximal uncovered 
descending aorta
2 19 Chronic dissection; progressive 72 Aneurysm size unchanged at 1 y
aneurysm enlargement
3 16 Extension of chronic dissection— 55 Stable with no recurrence; 50% 
back pain reduction in false lumen flow at 12 mo
4 3 Acute dissection; chest pain; 35 Emergency use–3 d hospitalization with
extravasation of contrast on CT complete recovery. Died at 3 mo of 
renal and pulmonary failure—
unknown cause
5 8 Chronic dissection, recurrent  50 Pain relieved; TAA diameter decreased 
chest and back pain by 2 mm at 6 mo
6 7 Acute dissection, severe back and 40 Complete recovery by 30 d 
chest pain; obtruded after 24 h postprocedure
7 6 Chronic dissection with acute 50 Pain relieved; TAA diameter decreased 
extension; back pain by 3 mm at 6 mo
8 6 Chronic dissection with acute 53 Pain resolved; dissection not visible on
extension; back pain 6-mo CT
9 5 Thoracoabdominal dissection with 50 Pain relieved; TAA diameter decreased 
recurrent chest pain by 2 mm at 6 mo
Fig 4. A 62-year-old man with severe cardiomyopathy and both TAAs (55 mm) and AAAs (60 mm). Simultaneous repair of both lesions
with endografts was successfully accomplished while the patient received local anesthesia.
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DISCUSSION
Dr Douglas P. Grey (San Francisco, Calif). Dr White and his
colleagues are to be congratulated at their groundbreaking effort
in the field, which has now set a benchmark for therapy in this dif-
ficult clinical situation.
First, the “Good News”: This paper has all of the intraoper-
ative elements of superb results of low blood loss, efficient oper-
ating time, short intensive care and hospital stays, and early return
to a functional existence. Most startling is the 4% paraplegia rate
and postoperative death rate in the whole group. This is men-
tioned in stark contrast to other reports of open repair, particu-
larly in the patients with nonaneurysmal dissections. One
unmentioned advance is the absence of segmental thoracic
ischemia that may lead to incisional complications, particularly in
the populations requiring redo surgery.
Now the “Bad News”: There was one procedural death and
five postoperative deaths (the latter called “device unrelated”)
leading to a combined mortality of 25% in the follow-up period
with a mean of 9 months. This may raise questions of the expec-
tations of the outcome for patients undergoing this procedure.
Furthermore, seven patients required reconstruction of the
femoral and or iliac artery because of trauma of the introducer
sheath (24F). Although this procedure exchanges a major
chronic problem for a relatively minor chronic problem, this is a
number that is higher than would have been expected in
patients undergoing routine femoral arterial cannulation for
femoral perfusion.
Finally, I would like to pose several questions to the authors.
Are we being misled by the size criteria for repair? A 5-cm
aneurysm of the thoracic aorta has little risk of rupture. You have
included the patients with symptomatic descending dissections,
which despite their small size, are a particularly hazardous group
in and of themselves. The size for repair as an operative indication
may be less relevant. When the many adjuncts for the prohibition
or reduction of paraplegia such as CSF drainage have been
demonstrated in the operative group, are you planning on the
incorporation of these to even further reduce or eliminate the
chance of paraplegia? Given the improvement in imaging and
potential localization of key intercostal arteries, have you given
any thought to creative ways to reimplantation? With your
extremely low paraplegia rate, this question may only be theoret-
ical since your technique may make this point moot. Given the
rather high postoperative mortality, particularly in the follow-up
period, would it be useful to stratify the deaths to facilitate better
case selection for a more durable patient population? Finally, as
you have so honestly attempted to point out, many surgeons cur-
rently have a financial interest in the companies that they discuss
in reports of technological advancement. Should this be of con-
cern to either the audience to whom they speak or the societies
that provide the forum for presentation?
Finally, could I impose on the President to poll the audience
regarding whether they would have this procedure performed on
them, should they need it? In contrast to the carotid artery stent-
ing, where the alternative is less odious, I would estimate that Dr
White has today convinced us with a very compelling argument
that would convert even the most skeptical among us.
Dr Rodney A. White. The first questions related to the diam-
eter of the aneurysms. We would agree. What I gave was a num-
ber all inclusive for everybody included in the study, and as you’ve
mentioned, that includes the dissections. Most of the smaller
aneurysms were, in fact, the patients with dissections or a couple
that had perforated. One lady had a hemothorax. We identified
the site, not even really an aneurysm there, but she was treated as
an extravasation.
So again, the average diameter, if we eliminated those
patients who were treated for a perforated ulcer or a dissection, is
much greater. As I showed you, there are several 8-, 9-, and 10-
cm aneurysms. We would agree that five is marginal. Six is prob-
ably okay. In the current literature, which has looked at this if
they’re rapidly expanding and they’re six, they’re probably indi-
cated, and we would say the same.
Regarding adjuncts for paraplegia, we have really thought
about this, although at the present time we’re doing all these
patients under local anesthesia. In this particular patient, as soon
as they called me, we did spinal drainage on him. He did recover
a little bit of function but then lost it. What we’ve done, I guess,
as an adjunct is to keep them in the unit, keep their pressure up,
and we have not considered anticoagulation or anything else, but
certainly that’s fair game and we would look at that.
The other thing we have done, as you’ve recommended, is to
look not only on the CT scans but with intravascular ultrasound
at any branch vessels, and we particularly do anything we can to
avoid covering those. With the combination of those two, we
rarely, if ever, cover anything. In the particular patient who had
the paraplegia, he’s the guy we would have least expected. This
was a nice fusiform 8-cm aneurysm, no branch vessels. We still
can’t find anything that we covered going back looking over this,
and he had paraplegia.
Now, to make it a little bit longer, he’s one of those who had
an iliac reconstruction. We tried to deploy a device from one side
and were unsuccessful, came back later, and did the other side
with a conduit. So we probably did affect both hypogastric circu-
lations, and in a patient like this that may have been the reason
rather than covering something in the chest.
So the access point, which was another one of your questions,
was particularly relevant. Part of the access issues were that in this
study, about 50% of our patients were female. That’s sort of
unusual for the normal distribution, but the catheter sizes are
large. When access isn’t an issue, these are very quick procedures.
Regarding the stratifications of patients, although four of
these were declared emergencies and didn’t fit the protocol, most
of these folks were really sick and were not considered surgical
candidates. So I think this is not a surgical population at all. If we
were to pick those who were good surgical candidates, my expec-
tation would be if they had good access the numbers would be
better. So that even though there is a high, as you’ve mentioned,
mortality rate in that group, this is comparable to what’s reported
in the literature for standard surgical procedures.
Again, I think this group is sicker, and most of the patients
who died had some intercurrent illness. Because we are doing
them under local, we actually don’t worry about whether they’re
surgical candidates anymore. If they can lay down and get local
anesthesia, they qualify if we have access. So I think it’s a differ-
ent group of folks, and they understand the risk, but the point is
well taken.
Regarding the question about financial interest, I think it is
very important. This has been addressed, and we also, as Dr
Zarins brought up last night, as surgeons need to realize that our
financial conflict is that we do surgery and get paid for it and per-
haps recommend surgery without fully disclosing all factors. As I
said, I am conflicted from all regards and I’ll admit it. Regardless,
these are the data.
Dr Christopher Zarins (Stanford, Calif). Thank you very
much for bringing this very important information and excellent
results. My question relates to how we actually get this type of
technology available for out patients. You have told us that you’re
doing this under local anesthesia on anyone who will lie still.
The FDA requires a clinical trial comparing this procedure
against standard open surgery. It seems like we have a little bit of
a conflict there because in order to make the technology available
to our patients, it has to pass FDA muster with a controlled clini-
cal trial. Now, is it an appropriate requirement of the FDA to have
open surgery as the control, which is what FDA is requiring right
now as you know? You are not following this tenant. You are oper-
ating under a local in patients who are not surgical candidates.
So how are we every going to get this technology available
for our patients if we don’t address this issue?
Dr White. Well, that’s an important point. Actually as part of
the Phase I study no surgery controls were required here, but for
Phase II they are and Gore may want to comment. It’s a one-to-
three basis, and it’s concurrent. So it isn’t exactly a controlled
entry, but they want concurrent data.
Dr Mark Nehler (Denver, Colo). Do you think that with your
increase in technical ability to do these procedures (and you’re
going to be faced with higher and higher risk patients because
people are going to start realizing that it can be done) that you’re
going to have to start changing outcomes so that 30-day mortal-
ity won’t be as important as whether or not somebody is alive in
a year, especially with how expensive devices are and perhaps if
people die at 2 or 3 months that’s still considered a failure from
a public health standpoint?
Dr White. Yes. It’s changed us some. As I’ve shown you, the
one patient whom we had, the guy with blood in his chest, had
several transfusions, his cardiac output was low, and he was in renal
failure. We were able to convert what would have been a very pro-
longed hospital stay and no surgery, a very expensive thing, to a
short stay and him out. Now, he did still die of congestive failure,
but that interim treatment helped him significantly.
Several of the other patients who died were acutely ill with no
alternative, and I think they would have had a very long, pro-
longed and high death rate with surgery.
With some of these data, I don’t think you need a surgical
series for, as Chris has pointed out, because to operate on some
of these folks, some very aggressive thoracic surgeons said, “No,
we can’t do this. You can,” and the patients agreed. So I think it’s
unethical to do a study under those circumstances.
So the end points are different, but if you can get folks in and
out without transfusion, it’s sort of like doing a portacaval shunt
in a patient who you still know is going to bleed to death. Is it
cost-effective, and are there reasons to do it? I think yes. So end
points are part of that. We need to redefine them.
Dr Robert Rutherford (Silverthorne, Colo). Obviously
there’s some real tangible benefits to this approach over open
surgery as you can tell from all the hands that went up in the
audience.
Currently using the devices available, could you tell us in
general what the inclusion and exclusion criteria, the anatomic
ones, are for doing this procedure, and roughly now what percent
of all thoracic abdominal aortic aneurysms presenting do you
think you could attack with this approach?
Dr White. The current criteria for this protocol are that the
aneurysms are larger than five and that there are adequate fixation
sites in the distal thoracic aorta. If you really took our data and com-
pared them with what those entry criteria are, I’m sure that just as
with the abdominal protocols, a lot of these folks don’t fit. 
So these studies all tend to treat sicker patients for whatever
kind of reason. So I think that’s part of it. The other is I have no
idea what percentage of patients qualify. I do know that where we
get referrals now, there are thoracic surgeons who have been fol-
lowing patients for a long time who finally say they were too high
risk, but they need to be treated. They’re enlarged.
So I think this is a select group. It’s only descending,
although eventually, devices are going to come around that will
treat the entire length of the aorta. This is a small percentage but
a significant one. The dissections are a very impressive group
because they can be treated very easily and quickly, and there’s no
doubt in them when you can do them under local anesthesia and
get them out quickly with the preliminary data that they will
regress and do very well is impressive.
So I couldn’t give you a good estimate. It’s a small percent-
age now, but I think it could rapidly expand if the technology gets
developed. Certainly it’s hard to say there isn’t an advantage for
that group.
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